G. Köhler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.3, issue.5517, pp.495-497, 1975.
DOI : 10.1038/256495a0

J. Folkman, Tumor angiogenesis: therapeutic implications, N Engl J Med, vol.285, pp.1182-1186, 1971.

N. Ferrara, K. Hillan, H. Gerber, and W. Novotny, Case history: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nature Reviews Drug Discovery, vol.81, issue.5, pp.391-400, 1381.
DOI : 10.1038/nrd1381

H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, and J. Hainsworth, Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.350, issue.23, pp.2335-2342, 2004.
DOI : 10.1056/NEJMoa032691

M. Cohen, Y. Shen, P. Keegan, and R. Pazdur, FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme, The Oncologist, vol.14, issue.11, pp.1131-1138, 2009.
DOI : 10.1634/theoncologist.2009-0121

J. Lu, R. Bruno, S. Eppler, W. Novotny, and B. Lum, Clinical pharmacokinetics of bevacizumab in patients with solid tumors, Cancer Chemotherapy and Pharmacology, vol.28, issue.5, pp.779-786, 2008.
DOI : 10.1007/s00280-007-0664-8

D. Ternant, N. Cézé, T. Lecomte, D. Degenne, and A. Duveau, An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics, Therapeutic Drug Monitoring, vol.32, issue.5, pp.647-652, 2010.
DOI : 10.1097/FTD.0b013e3181ef582a

URL : https://hal.archives-ouvertes.fr/hal-00616329

V. Ranpura, S. Hapani, and S. Wu, Treatment-Related Mortality With Bevacizumab in Cancer Patients, JAMA, vol.305, issue.5, pp.487-494, 2011.
DOI : 10.1001/jama.2011.51

D. Miles, A. Chan, L. Dirix, J. Cortés, and X. Pivot, Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2???Negative Metastatic Breast Cancer, Journal of Clinical Oncology, vol.28, issue.20, pp.3239-3247, 2010.
DOI : 10.1200/JCO.2008.21.6457

URL : https://hal.archives-ouvertes.fr/inserm-00508083

D. Reardon, A. Desjardins, K. Peters, S. Gururangan, and J. Sampson, Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab na??ve, recurrent glioblastoma, Journal of Neuro-Oncology, vol.8, issue.2, pp.155-164, 2012.
DOI : 10.1007/s11060-011-0722-2

I. Ordás, D. Mould, B. Feagan, and W. Sandborn, Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms, Clinical Pharmacology & Therapeutics, vol.135, issue.4, pp.635-646, 2012.
DOI : 10.1038/clpt.2011.328

D. Mould and B. Green, Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies, BioDrugs, vol.255, issue.21, pp.23-39, 2010.
DOI : 10.2165/11530560-000000000-00000

B. Houser, Bio-Rad???s Bio-Plex?? suspension array system, xMAP technology overview, Archives of Physiology and Biochemistry, vol.118, issue.4, pp.192-196, 2012.
DOI : 10.1172/JCI104130

D. Mould and K. Sweeney, The pharmacokinetics and pharmacodynamics of monoclonal antibodies?mechanistic modeling applied to drug development, Curr Opin Drug Discov Devel, vol.10, pp.84-96, 2007.

K. Margolin, M. Gordon, E. Holmgren, J. Gaudreault, and W. Novotny, Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data, Journal of Clinical Oncology, vol.19, issue.3, pp.851-856, 2001.
DOI : 10.1200/JCO.2001.19.3.851

J. Kim, C. Bronson, W. Hayton, M. Radmacher, and D. Roopenian, Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces, AJP: Gastrointestinal and Liver Physiology, vol.290, issue.2, pp.352-360, 2005.
DOI : 10.1152/ajpgi.00286.2005

G. Wilkinson, Drug Metabolism and Variability among Patients in Drug Response, New England Journal of Medicine, vol.352, issue.21, pp.2211-2221, 2005.
DOI : 10.1056/NEJMra032424